View Post

Rare Patient Voice: Study Opportunity for Cervical Cancer Patients

In Paid Opportunities For The Cancer Community by Barbara Jacoby

Study Details: 60 min Web-Assisted Phone Interview Compensation $125 Please sign up at the link below for more information or to see if you qualify. https://rarepatientvoice.com/LetLifeHappen/ Why Sign up with Rare Patient Voice? Who knows better than you about your journey and experiences?  We connect you with researchers who are developing products and services which can help you and others …

View Post

Estradiol Challenge Test ‘Highly Predictive’ of Response to Endocrine Therapy in Patients With ER-Positive Breast Cancer

In Clinical Trials by Barbara Jacoby

By: Leah Lawrence From: cancertherapyadvisor.com The use of a positron emission tomography (PET)-based estradiol challenge test was found to be highly predictive of response to endocrine therapy in women with estrogen-receptor (ER)-positive breast cancer. In the phase 2 study (NCT02455453), data from which were published in Nature Communications, the investigators measured the responses to endocrine therapy by monitoring the change …

View Post

Advances in X-ray imaging can help patients with breast cancer

In In The News by Barbara Jacoby

By: University College London From: medicalxpress.com A new X-ray imaging scanner to help surgeons performing breast tumor removal surgery has been developed by UCL experts. Most breast cancer operations are what are known as conserving surgeries, which remove the cancerous tumor rather than the whole breast. Second operations are often required if the margins (edges) of the extracted tissue are …

View Post

Savvy Cooperative: People living with non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC) or breast cancer

In Paid Opportunities For The Cancer Community by Barbara Jacoby

SCREENER Description: We’re looking for folks who have been diagnosed with cancer and have received treatment in the last 12 months Eligibility Criteria: Adult who has been diagnosed with non-small cell lung cancer, small cell lung cancer or breast cancer NOTE: Only patients with verified diagnoses will be considered US resident Details: 60-minute patient experience interview From home Receive: $100 …

View Post

Phase 3 OlympiA Trial for HER2-Negative Breast Cancer Moves to Early Primary Analysis Per IDMC Recommendation

In Clinical Trials by Barbara Jacoby

By: Hannah Slater From: cancernetwork.com In the OlympiA trial, patients with high-risk HER2-negative breast cancer were randomized 1:1 to receive either olaparib or placebo for 12 months. A planned interim analysis found that the phase 3 OlympiA trial (NCT02032823) crossed the superiority boundary for its primary end point of invasive disease-free survival (iDFS) and demonstrated a sustainable, clinically relevant treatment …

View Post

FibroGenesis Reports Positive Preclinical Data in Pancreatic and Breast Cancer Using “Universal Acting” Fibroblast Based Immunotherapy

In In The News by Barbara Jacoby

Source: FibroGenesis From: prnewswire.com Novel Approach Successfully Induces Regression of Established Tumors by Focusing Immunotherapy to Target “Achilles Heel” of Cancer FibroGenesis, a clinical stage company developing fibroblast-based therapeutic solutions for unmet medical needs, announced today new data supporting utilizing its fibroblast-based immunotherapy for successful inhibition and induction of regression in preclinical models of breast cancer and pancreatic cancer. Company …

View Post

Savvy Cooperative: Patients diagnosed with cancer and have received treatment in the last 12 months

In Paid Opportunities For The Cancer Community by Barbara Jacoby

SCREENER Description: We’re looking for folks who have been diagnosed with cancer and have received treatment in the last 12 months Eligibility Criteria: Adult who has been diagnosed with cancer NOTE: Only patients with verified diagnoses will be considered Received treatment for cancer within the last 12 months US resident Details: Design review and user testing 60-minute virtual interview From …

View Post

Bard1 Life Sciences (ASX:BD1) reveals tech’s efficiency in detecting breast cancer

In Clinical Trials by Barbara Jacoby

By: Samantha Goerling From: themarketherald.com.au Australian diagnostics company Bard1 Life Sciences (BD1) has revealed its SubB2M technology can detect all stages of breast cancer from a blood sample. Research completed by the Griffith University’s Institute for Glycomics found the technology could detect the cancer with 100 per cent specificity and 95 per cent sensitivity. “A non-invasive, accurate and reliable blood test …

View Post

Congress must close gaps in insurance for breast cancer patients | PennLive letters

In In The News by Barbara Jacoby

From: pennlive.com World Cancer Day was celebrated Feb. 4, and I would like to draw attention to the often neglected survivorship issue of lymphedema. This incurable, but treatable condition affects 15% of cancer survivors overall, 40% of all breast cancer survivors as well as others, like myself, who suffer from the condition and didn’t have cancer surgery. When cancer treatments …

View Post

Pyrotinib plus capecitabine versus lapatinib plus capecitabine for the treatment of HER2-positive metastatic breast cancer (PHOEBE)

In Clinical Trials by Barbara Jacoby

From: thelancet.com A multicentre, open-label, randomised, controlled, phase 3 trial Background Despite therapeutic advances in HER2-positive metastatic breast cancer, resistance to trastuzumab inevitably develops. In the PHOEBE study, we aimed to assess the efficacy and safety of pyrotinib (an irreversible pan-HER inhibitor) plus capecitabine after previous trastuzumab. Methods This is an open-label, randomised, controlled, phase 3 trial done at 29 …